Letters To The Editor
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 14, 2013; 19(10): 1669-1670
Published online Mar 14, 2013. doi: 10.3748/wjg.v19.i10.1669
Response letter regarding the interpretation of gene expression data
Fusun Ozmen
Fusun Ozmen, Department of Basic Oncology, Cancer Institute, Hacettepe University, 06280 Ankara, Turkey
Author contributions: Ozmen F wrote this letter.
Correspondence to: Fusun Ozmen, MD, PhD, Department of Basic Oncology, Cancer Institute, Hacettepe University, 06280 Ankara, Turkey. fusun.ozmen@hacettepe.edu.tr
Telephone: +90-312-3054322 Fax: +90-312-3242009
Received: December 26, 2012
Revised: January 10, 2013
Accepted: January 18, 2013
Published online: March 14, 2013
Processing time: 77 Days and 22 Hours
Abstract

This is a response letter to Verna E’s comments regarding our previous manuscript published last year in the World Journal of Gastroenterology entitled “Relationship between LYVE-1, VEGFR-3 and CD44 gene expressions and lymphatic metastasis in gastric cancer”, which evaluated the relationship between these expression levels and clinicopathological parameters (Ozmen F et al, World J Gastroenterology 2011; 17: 3220-3228). The mean values for lymphatic vessel endothelial hyaluronan receptor-1, CD44 and vascular endothelial growth factor receptor-3 expression (represented as 2-ΔΔCt) were 1.13, 1.24 and 1.17, respectively, suggesting an increase in gene expression in tumor tissue compared to normal tissue. Despite the increase in gene expression in the cancer tissues (2-ΔΔCt > 1), only some of the results reached statistical significance, which was thoroughly discussed in our paper. In the present letter, we report that his comments are flawed and result in confusion. Therefore, we herein provide more explanation regarding gene expression in gastric cancer. We hope that this letter will address Verna E’s misunderstandings.

Keywords: Gastric cancer; Lymphatic metastasis; Lymphatic vessel endothelial hyaluronan receptor-1; Vascular endothelial growth factor receptor-3; CD44